119 related articles for article (PubMed ID: 9366448)
1. Prevention of immunotoxin-induced immunogenicity by coadministration with CTLA4Ig enhances antitumor efficacy.
Siegall CB; Haggerty HG; Warner GL; Chace D; Mixan B; Linsley PS; Davidson T
J Immunol; 1997 Nov; 159(10):5168-73. PubMed ID: 9366448
[TBL] [Abstract][Full Text] [Related]
2. Clinical evaluation of BR96 sFv-PE40 immunotoxin therapy in canine models of spontaneously occurring invasive carcinoma.
Henry CJ; Buss MS; Hellström I; Hellström KE; Brewer WG; Bryan JN; Siegall CB
Clin Cancer Res; 2005 Jan; 11(2 Pt 1):751-5. PubMed ID: 15701865
[TBL] [Abstract][Full Text] [Related]
3. BR96 sFv-PE40 immunotoxin: nonclinical safety assessment.
Haggerty HG; Warner WA; Comereski CR; Peden WM; Mezza LE; Damle BD; Siegall CB; Davidson TJ
Toxicol Pathol; 1999; 27(1):87-94. PubMed ID: 10367679
[TBL] [Abstract][Full Text] [Related]
4. Targeted therapy of carcinomas using BR96 sFv-PE40, a single-chain immunotoxin that binds to the Le(y) antigen.
Siegall CB
Semin Cancer Biol; 1995 Oct; 6(5):289-95. PubMed ID: 8562906
[TBL] [Abstract][Full Text] [Related]
5. Antitumor activity of the single-chain immunotoxin BR96 sFv-PE40 against established breast and lung tumor xenografts.
Friedman PN; Chace DF; Trail PA; Siegall CB
J Immunol; 1993 Apr; 150(7):3054-61. PubMed ID: 8454873
[TBL] [Abstract][Full Text] [Related]
6. In vitro and in vivo characterization of BR96 sFv-PE40. A single-chain immunotoxin fusion protein that cures human breast carcinoma xenografts in athymic mice and rats.
Siegall CB; Chace D; Mixan B; Garrigues U; Wan H; Paul L; Wolff E; Hellström I; Hellström KE
J Immunol; 1994 Mar; 152(5):2377-84. PubMed ID: 8133048
[TBL] [Abstract][Full Text] [Related]
7. BR96 sFv-PE40, a potent single-chain immunotoxin that selectively kills carcinoma cells.
Friedman PN; McAndrew SJ; Gawlak SL; Chace D; Trail PA; Brown JP; Siegall CB
Cancer Res; 1993 Jan; 53(2):334-9. PubMed ID: 8417827
[TBL] [Abstract][Full Text] [Related]
8. Prevention of immunotoxin-mediated vascular leak syndrome in rats with retention of antitumor activity.
Siegall CB; Liggitt D; Chace D; Tepper MA; Fell HP
Proc Natl Acad Sci U S A; 1994 Sep; 91(20):9514-8. PubMed ID: 7937798
[TBL] [Abstract][Full Text] [Related]
9. Cardiac allograft tolerance induced by intra-arterial infusion of recombinant adenoviral CTLA4Ig.
Yang Z; Rostami S; Koeberlein B; Barker CF; Naji A
Transplantation; 1999 Jun; 67(12):1517-23. PubMed ID: 10401757
[TBL] [Abstract][Full Text] [Related]
10. Antitumor activity of carcinoma-reactive BR96-doxorubicin conjugate against human carcinomas in athymic mice and rats and syngeneic rat carcinomas in immunocompetent rats.
Sjögren HO; Isaksson M; Willner D; Hellström I; Hellström KE; Trail PA
Cancer Res; 1997 Oct; 57(20):4530-6. PubMed ID: 9377565
[TBL] [Abstract][Full Text] [Related]
11. Differential effect of CTLA4Ig on murine graft-versus-host disease (GVHD) development: CTLA4Ig prevents both acute and chronic GVHD development but reverses only chronic GVHD.
Via CS; Rus V; Nguyen P; Linsley P; Gause WC
J Immunol; 1996 Nov; 157(9):4258-67. PubMed ID: 8892665
[TBL] [Abstract][Full Text] [Related]
12. Effect of administration of CTLA4-Ig as protein or cDNA on corneal allograft survival.
Comer RM; King WJ; Ardjomand N; Theoharis S; George AJ; Larkin DF
Invest Ophthalmol Vis Sci; 2002 Apr; 43(4):1095-103. PubMed ID: 11923251
[TBL] [Abstract][Full Text] [Related]
13. Assessment of dose proportionality, absolute bioavailability, and immunogenicity response of CTLA4Ig (BMS-188667), a novel immunosuppressive agent, following subcutaneous and intravenous administration to rats.
Srinivas NR; Shyu WC; Weiner RS; Warner G; Comereski C; Tay LK; Greene DS; Barbhaiya RH
Pharm Res; 1997 Jul; 14(7):911-6. PubMed ID: 9244149
[TBL] [Abstract][Full Text] [Related]
14. A phase I trial of the single-chain immunotoxin SGN-10 (BR96 sFv-PE40) in patients with advanced solid tumors.
Posey JA; Khazaeli MB; Bookman MA; Nowrouzi A; Grizzle WE; Thornton J; Carey DE; Lorenz JM; Sing AP; Siegall CB; LoBuglio AF; Saleh MN
Clin Cancer Res; 2002 Oct; 8(10):3092-9. PubMed ID: 12374676
[TBL] [Abstract][Full Text] [Related]
15. Single-chain fusion toxins for the treatment of breast cancer: antitumor activity of BR96 sFv-PE40 and heregulin-PE40.
Siegall CB
Recent Results Cancer Res; 1996; 140():51-60. PubMed ID: 8787077
[No Abstract] [Full Text] [Related]
16. Toxic shock syndrome toxin-1-induced death is prevented by CTLA4Ig.
Saha B; Jaklic B; Harlan DM; Gray GS; June CH; Abe R
J Immunol; 1996 Nov; 157(9):3869-75. PubMed ID: 8892617
[TBL] [Abstract][Full Text] [Related]
17. Activity of a single-chain immunotoxin that selectively kills lymphoma and other B-lineage cells expressing the CD40 antigen.
Francisco JA; Gilliland LK; Stebbins MR; Norris NA; Ledbetter JA; Siegall CB
Cancer Res; 1995 Jul; 55(14):3099-104. PubMed ID: 7541711
[TBL] [Abstract][Full Text] [Related]
18. Preventing allograft rejection with CTLA4IG: effect of donor-specific transfusion route or timing.
Bolling SF; Lin H; Wei RQ; Turka LA
J Heart Lung Transplant; 1996 Sep; 15(9):928-35. PubMed ID: 8889989
[TBL] [Abstract][Full Text] [Related]
19. CTLA4Ig inhibits airway eosinophilia and hyperresponsiveness by regulating the development of Th1/Th2 subsets in a murine model of asthma.
Padrid PA; Mathur M; Li X; Herrmann K; Qin Y; Cattamanchi A; Weinstock J; Elliott D; Sperling AI; Bluestone JA
Am J Respir Cell Mol Biol; 1998 Apr; 18(4):453-62. PubMed ID: 9533932
[TBL] [Abstract][Full Text] [Related]
20. CD28-B7 T cell costimulatory blockade by CTLA4Ig in sensitized rat recipients: induction of transplantation tolerance in association with depressed cell-mediated and humoral immune responses.
Onodera K; Chandraker A; Schaub M; Stadlbauer TH; Korom S; Peach R; Linsley PS; Sayegh MH; Kupiec-Weglinski JW
J Immunol; 1997 Aug; 159(4):1711-7. PubMed ID: 9257832
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
